证券代码：002793 证券简称：罗欣药业 公告编号：2026-002 罗欣药业集团股份有限公司 关于为控股子公司提供担保的进展公告 特别提示： 罗欣药业集团股份有限公司（以下简称"公司""上市公司"）及控股子公 司对外担保总额超过最近一期经审计净资产 100%；公司及控股子公司担保金额 超过上市公司最近一期经审计净资产 50%，提请投资者充分关注担保风险。 一、担保情况概述 公司及控股子公司为满足日常生产经营及业务拓展资金需要，保证其生产经 营持续发展和业务顺利开展，2025 年度拟为控股子公司提供总额度不超过人民 币 6.48 亿元的担保（不含单事单议和已履行董事会和股东大会审议程序的担保 额度）。其中，公司为山东罗欣药业集团股份有限公司（以下简称"山东罗欣"） 提供担保额度人民币 50,500 万元。公司分别于 2025 年 4 月 21 日、2025 年 5 月 12 日召开第五届董事会第二十四次会议、第五届监事会第二十一次会议及 2024 年年度股东大会，审议通过了《关于 2025 年度向金融机构申请综合授信额度及 对外担保的议案》，上述担保额度有效期限自股东大会审议通过之日起 12 个月。 具 体 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 2025 年 12 月 22 日，罗欣药业集团股份有限公司（以下简称"公司"）召 开第五届董事会第三十四次会议，审议通过了《关于转让控股子公司股权的议案》， 同意公司下属子公司山东罗欣药业集团股份有限公司（以下简称"山东罗欣"） 将其持有的罗欣安若维他药业（成都）有限公司（以下简称"罗安公司"）20% 股权以 5,125,000 美元转让给 Helix Healthcare B.V.（以下简称"Helix"）。本次 股权转让前，山东罗欣持有罗安公司 70%股权，本次股权转让完成后，山东罗欣 持有罗安公司 50%股权，罗安公司将不再纳入公司合并报表范围。山东罗欣与 Helix 于 2025 年 12 月 22 日签署了《关于罗欣安若维他药业（成都）有限公司的 股权转让协议》。具体内容详见公司于 2025 年 12 月 24 日刊登于巨潮资讯网 （http://www.cninfo.com.cn）的《关于转让控股子公司股权的公告》。 证券代码：002793 股票简称：罗欣药业 公告编号：2026-003 ...

罗欣药业公告称，2025年公司董事会同意下属子公司山东罗欣将罗安公司20%股权以512.5万美元转让 给Helix。转让前，山东罗欣持有罗安公司70%股权；近日完成工商变更登记后，持股降至50%，罗安公 司不再纳入合并报表。截至公告日，公司为罗安公司提供的连带责任保证担保已全部解除，山东罗欣对 罗安公司借款等应收款项均已结清，罗安公司预付货款由397.37万元减至85.34万元。 ...

（文章来源：证券日报） 证券日报网讯 01月5日，罗欣药业在互动平台回答投资者提问时表示，截至2025年12月31日，公司股东 总户数为38648户。 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2026-001 董事会秘书联系方式如下： 联系电话：021-38867666 传真号码：021-38867600 电子邮箱：IR@luoxin.cn 通讯地址：上海市浦东新区东育路 255 弄 4 号前滩世贸中心一期 A 栋 7 层 罗欣药业集团股份有限公司 关于公司董事会秘书取得任职培训证明的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 罗欣药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 13 日召 开第五届董事会第三十一次会议，审议通过了《关于聘任董事会秘书的议案》， 为完善公司治理结构，确保公司规范运作，经公司董事长提名，董事会提名委员 会审查，董事会同意聘任姜英女士为公司董事会秘书，任期自董事会审议通过之 日起至第五届董事会届满之日止。具体内容详见公司 2025 年 10 月 14 日刊登于 巨潮资讯网（http://www.cninfo.com.cn）、《上海证券报》的《关于聘任董事会 秘书的公告》。 近日，姜英女士已取得了深圳证券交易所颁发的上市公司董事会秘书培训证 ...

Core Viewpoint - 罗欣药业 is strategically focusing on the pharmaceutical industry, with significant growth in its core innovative drug, 泰欣赞, and plans for further development in the digestive system field. Group 1: Company Performance - As of December 31, 2025, 罗欣药业's stock closed at 4.8 yuan, down 1.44% from the previous week, with a total market capitalization of 5.22 billion yuan, ranking 97th in the chemical pharmaceutical sector [1] - 泰欣赞's sales volume increased by nearly 140% year-on-year, with the number of hospitals using the drug approaching 2,500 [1][4] - The gross profit margin for the first three quarters reached 51.8%, and operating cash flow turned positive at 280 million yuan [4] Group 2: Product Development - 泰欣赞 has achieved full coverage in the medical insurance directory for its three indications: gastroesophageal reflux disease, duodenal ulcers, and eradication of Helicobacter pylori [1][4] - The drug's advantages over PPI include rapid onset, prolonged acid suppression, and effective control of nighttime acid breakthrough [1] - The company is advancing its research pipeline, with the injection drug LX22001 entering phase II clinical trials and the report for the phase III clinical study of 普卡那肽片 completed [1] Group 3: Strategic Initiatives - 罗欣药业 plans to raise up to 842.4 million yuan through a refinancing project aimed at funding innovative drug research, raw material drug expansion, and supplementing working capital [2][4] - The company is optimizing processes for potential centralized procurement products and building a product matrix that supports innovative drugs and differentiated generics [2] Group 4: Corporate Transactions - 罗欣药业's subsidiary, 山东罗欣, intends to transfer its 100% stake in 山东罗欣乐康制药有限公司 for a consideration of 62.5 million yuan, which will no longer be included in the consolidated financial statements post-transaction [2][4]

Core Viewpoint - Luoxin Pharmaceutical Group Co., Ltd. has shown significant growth in its core product, Tegoprazan (brand name: Taixinzan®), with a nearly 140% year-on-year increase in sales in the first half of 2025, supported by favorable medical insurance policies and improved profitability [1][3][4]. Group 1: Investor Activity - The investor relations activity was conducted from December 28 to 29, 2025, involving both online and offline formats, with participation from major investment institutions [2]. - The company’s board secretary, Jiang Ying, addressed key investor concerns regarding product progress, financial performance, and research and development [2]. Group 2: Product Performance - Tegoprazan, classified as a first-class innovative drug and a P-CAB (potassium-competitive acid blocker), has made significant market advancements, with nearly 2,500 hospitals adopting the product in the first half of 2025 [3]. - The product's sales volume increased by nearly 140% compared to the previous year, and it has been included in the national medical insurance directory for three major indications, which will further enhance market penetration [3]. Group 3: Financial Performance - The company reported a gross margin of 51.8% for the first three quarters of 2025, an increase of 9 percentage points year-on-year, and a positive operating cash flow of 280 million yuan [4]. - The improvement in financial metrics is attributed to the scaling up of Tegoprazan sales and effective management of operating capital [4]. Group 4: Research and Development - The company’s R&D team focuses on unmet clinical needs in the digestive system and implements a differentiated strategy for generic drugs, ensuring supply and cost control for selected products [5]. - A plan to raise up to 842.4 million yuan through a private placement of A-shares has been approved, aimed at funding innovative drug development and expanding production capacity [5]. Group 5: Overall Outlook - Overall, Luoxin Pharmaceutical is positioned for growth driven by its innovative drug, with ongoing improvements in product structure and financial indicators, supported by research investments and refinancing efforts [7].

Core Viewpoint - The company has decided to terminate the public listing for the sale of its subsidiary, LeKang Pharmaceutical, due to a lack of qualified buyers after one year and will instead transfer the ownership to LinYi JunKang for 62.5 million RMB [1] Group 1: Company Actions - The company held its 19th meeting of the 5th Board of Directors on November 18, 2024, where it approved the proposal to publicly list the sale of its subsidiary's equity [1] - The company’s subsidiary, Shandong LuoXin, will transfer 100% of its stake in LeKang Pharmaceutical to LinYi JunKang for a consideration of 62.5 million RMB [1] - Following the transfer, Shandong LuoXin will no longer hold any equity in LeKang Pharmaceutical, which will be excluded from the company’s consolidated financial statements [1] Group 2: Financial Implications - Prior to the transfer, Shandong LuoXin provided a loan of 2.8 million RMB to LeKang Pharmaceutical, which remains outstanding with a total amount of 2.8005 million RMB including interest [1] - The outstanding loan amount is expected to be settled by October 26, 2026, as confirmed by all parties involved [1]

每经AI快讯，罗欣药业（SZ 002793，收盘价：4.8元）12月29日晚间发布公告称，公司第五届第三十五 次董事会会议于2025年12月29日在山东省临沂高新技术产业开发区罗七路管理中心三楼会议室和上海市 浦东新区前滩世贸中心会议室以现场表决和通讯表决相结合的方式召开。会议审议了《关于转让控股子 公司股权暨被动形成财务资助的议案》。 截至发稿，罗欣药业市值为52亿元。 （记者 王晓波） 每经头条（nbdtoutiao）——绕开光刻机"卡脖子"，中国新型芯片问世！专访北大孙仲：支撑AI训练和 具身智能，可在28纳米及以上成熟工艺量产 2025年1至6月份，罗欣药业的营业收入构成为：医药工业占比88.11%，医药商业占比10.1%，其他业务 占比1.79%。 ...

关于终止挂牌出售子公司股权暨转让控股子公司股权暨被 动形成财务资助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、罗欣药业集团股份有限公司（以下简称"公司"、"上市公司"）下属 子公司山东罗欣药业集团股份有限公司（以下简称"山东罗欣"）拟将其持有的 山东罗欣乐康制药有限公司（以下简称"乐康制药"或"乐康公司"）100%的 股权转让给临沂君康生物有限公司（以下简称"临沂君康"），转让对价为人民 币 6,250 万元。本次股权转让前，山东罗欣持有乐康制药 100%股权；本次股权 转让后，山东罗欣不再持有乐康制药股权，乐康制药将不再纳入公司合并报表范 围。 2、在乐康制药属于公司合并报表范围内期间，为支持其业务发展，山东罗 欣为乐康制药提供的借款 280 万元借款本金，截至目前，乐康制药尚欠山东罗欣 280.05 万元本金及利息，上述借款及利息将因本次股权转让被动形成对外财务资 助。经各方确认，山东罗欣对乐康制药的最终借款及利息金额将于 2026 年 10 月 26 日内清偿完毕。 3、本次交易已经公司第五届董事会第三十五次会议审议通过， ...